SEARCH

SEARCH BY CITATION

References

  • 1
    Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66:36578.
  • 2
    Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:10469.
  • 3
    Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte (R)) in critically ill trauma patients: early results a randomized controlled trial. World J Surg 2006; 30:184855.
  • 4
    Zhang M, Liu B, Zhang Y, Wei H, Lei Y, Zhao L. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J Clin Microbiol 2007; 45:496500.
  • 5
    Zocco MA, Dal Verme LZ, Cremonini F et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23:156774.
  • 6
    Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4:5.
  • 7
    Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:12029.
  • 8
    Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:10814.
  • 9
    Lee YK, Puong KY. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. Br J Nutr 2002; 88 (Suppl. 1):S1018.
  • 10
    Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286:G61326.
  • 11
    Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64:522532.
  • 12
    Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:3027.
  • 13
    Pothoulakis C, Kelly CP, Joshi MA et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104:110815.
  • 14
    Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:98897.
  • 15
    Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992; 32:1414.
  • 16
    Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994; 10:5563.
  • 17
    Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr 2000; 54:84955.
  • 18
    Dogi CA, Perdigon G. Importance of the host specificity in the selection of probiotic bacteria. J Dairy Res 2006; 73:35766.
  • 19
    Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40:13745.
  • 20
    Cukrowska B, Lodinova-Zadnikova R, Enders C, Sonnenborn U, Schulze J, Tlaskalova-Hogenova H. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002; 55:2049.
  • 21
    Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:58091.
  • 22
    Jijon H, Backer J, Diaz H et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126:135873.
  • 23
    Ulisse S, Gionchetti P, D'Alo S et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96:26919.
    Direct Link:
  • 24
    Valdez JC, Peral MC, Rachid M, Santana M, Perdigon G. Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment. Clin Microbiol Infect 2005; 11:4729.
  • 25
    Wehkamp J, Harder J, Wehkamp K et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72:57508.
  • 26
    Porter EM, Poles MA, Lee JS, Naitoh J, Bevins CL, Ganz T. Isolation of human intestinal defensins from ileal neobladder urine. FEBS Lett 1998; 434:2726.
  • 27
    Ogushi KF, Wada AF, Niidome TF et al. Salmonella enteritidis FliC (flagella filament protein) induces hu beta-defensin-2 mRNA production by Caco-2 cells. J Biol Chem 2001; 276:305216.
  • 28
    Wehkamp J, Schmidt K, Herrlinger KR et al. Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status. J Clin Pathol 2003; 56:3527.
  • 29
    Christensen HR, Larsen CN, Kaestel P et al. Immunomodulating potential of supplementation with probiotics: a dose–response study in healthy young adults. FEMS Immunol Med Microbiol 2006; 47:38090.
  • 30
    Neish AS. Molecular aspects of intestinal epithelial cell–bacterial interactions that determine the development of intestinal inflammation. Inflamm Bowel Dis 2004; 10:15968.
  • 31
    Philpott DJ, Girardin SE, Sansonetti PJ. Innate immune responses of epithelial cells following infection with bacterial pathogens. Curr Opin Immunol 2001; 13:41016.
  • 32
    Rogler G, Brand K, Vogl D et al. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115:35769.
  • 33
    Berin MC, Darfeuille-Michaud A, Egan LJ, Miyamoto Y, Kagnoff MF. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol 2002; 4:63548.
  • 34
    Gewirtz AT, Rao AS, Simon PO Jr et al. Salmonella typhimurium induces epithelial IL-8 expression via Ca(2+)-mediated activation of the NF-kappaB pathway. J Clin Invest 2000; 105:7992.
  • 35
    Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165:90314.
  • 36
    Kim YG, Ohta T, Takahashi T et al. Probiotic Lactobacillus casei activates innate immunity via NF-kappaB and p38 MAP kinase signaling pathways. Microbes Infect 2006; 8:9941005.
  • 37
    Ruiz PA, Hoffmann M, Szcesny S, Blaut M, Haller D. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology 2005; 115:44150.
  • 38
    Larsen CN, Nielsen S, Kaestel P et al. Dose–response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 2006; 60:128493.
  • 39
    Petrof EO, Kojima K, Ropeleski MJ et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127:147487.
  • 40
    Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. The induction of human beta-defensin-2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75:2399407.
  • 41
    Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132:56275.
  • 42
    Coconnier-Polter MH, Lievin-Le MV, Servin AL. A Lactobacillus acidophilus strain of human gastrointestinal microbiota origin elicits killing of enterovirulent Salmonella enterica Serovar Typhimurium by triggering lethal bacterial membrane damage. Appl Environ Microbiol 2005; 71:611520.
  • 43
    Wagner RD, Pierson C, Warner T et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 1997; 65:416572.